Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cytokinetics (CYTK) Operating Income (2016 - 2025)

Cytokinetics (CYTK) has disclosed Operating Income for 16 consecutive years, with -$215.0 million as the latest value for Q4 2025.

  • Quarterly Operating Income changed N/A to -$215.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$648.9 million through Dec 2025, changed N/A year-over-year, with the annual reading at -$612.3 million for FY2025, 14.17% down from the prior year.
  • Operating Income for Q4 2025 was -$215.0 million at Cytokinetics, down from -$166.8 million in the prior quarter.
  • The five-year high for Operating Income was -$10.9 million in Q2 2022, with the low at -$215.0 million in Q4 2025.
  • Average Operating Income over 5 years is -$108.0 million, with a median of -$122.3 million recorded in 2023.
  • The sharpest move saw Operating Income tumbled 1434.9% in 2021, then skyrocketed 80.16% in 2022.
  • Over 5 years, Operating Income stood at -$21.7 million in 2021, then tumbled by 485.28% to -$127.0 million in 2022, then dropped by 0.31% to -$127.4 million in 2023, then decreased by 10.5% to -$140.8 million in 2024, then plummeted by 52.73% to -$215.0 million in 2025.
  • According to Business Quant data, Operating Income over the past three periods came in at -$215.0 million, -$166.8 million, and -$111.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.